Loading clinical trials...
Loading clinical trials...
A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma
Conditions
Interventions
Teclistamab Monotherapy
Teclistamab
Locations
13
United States
City of Hope
Duarte, California, United States
Emory Winship Cancer Center
Atlanta, Georgia, United States
University of Chicago Cancer Center
Chicago, Illinois, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana Farber Cancer Institute/Harvard Medical School
Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Center
Detroit, Michigan, United States
Start Date
November 17, 2024
Primary Completion Date
July 31, 2029
Completion Date
July 31, 2030
Last Updated
July 15, 2025
NCT06285318
NCT07523555
NCT06669247
NCT07497165
NCT04973605
NCT06138275
Lead Sponsor
Multiple Myeloma Research Consortium
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions